Liver cancer trial adds a resistance-blocker to standard chemo – could it boost success?

NCT ID NCT07302919

Recruiting now Disease control Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding nicardipine (a drug that blocks a cancer resistance protein) to standard chemoembolization (TACE) improves outcomes for people with liver cancer. About 152 adults with untreated liver tumors will be randomly assigned to receive either the standard TACE or TACE plus nicardipine. The main goal is to see if the combination leads to more complete tumor responses at 3 months and longer progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: doxorubicin and nicardipine loaded into drug-eluting beads
What this could lead to: If it works, this could improve the success rate of TACE for liver cancer, potentially leading to better tumor control and longer survival without progression.
What could go wrong: This is a mid-stage trial with only 152 participants, so results may not apply to all patients. Adding nicardipine could also increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATO CELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Hôpitaux Universitaires de Genève
RECRUITING

Geneva, 1205, Switzerland
Kantonsspital St. Gallen
RECRUITING

Sankt Gallen, 9007, Switzerland
University Hospital Basel
RECRUITING

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.